Track the 지씨셀 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 지씨셀 has logged 35 insider filings. Market capitalisation: €200.8bn. The latest transaction was filed on 9 March 2026 (Other). Among the most active insiders: 전지원. Every trade is accessible without an account.
28
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
n/a
2 ops.
Sell Volume
2Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,547 of 29,057 companies
24.1
score / 100
Value
24
Quality
24
FCF yld1.3%
Earn yld-135%
EV/EBITDA·
ROE-1.3%
Gross mgn18%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
지씨셀 es una empresa farmacéutica y de atención médica que cotiza en el XKRX. Se especializa en el desarrollo de soluciones innovadoras para el tratamiento de enfermedades.